# ACADIA PHARMACEUTICALS INC.

ISIN: US0042251084 WKN: 004225108 Asset Class: Stock



## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023	2022	2021
Financial figures	Assets Liabilities and equity	Assets Liabilities and equity	Assets Liabilities and equity
Current assets	-	-	-
Common stock capital		-	-
Fixed assets	-	-	-
Equity capital of a company		-	-
Cash and cash equivalents	-	-	-
Accrued liabilities		-	-
Other assets	-	-	-
Current liabilities		-	-
Prepayments and accrued income	-	-	
Non-current liabilities		-	-
Different income		-	-
Other liabilities		-	-
Total assets	-		-

### **Balance notes**

	2023	2022	2021
Accounting standard	-	-	-
Employees	-	-	-
Equity ratio	57.65%	68.12%	77.26%
Debt-equity ratio	73.47%	46.80%	29.44%

#### Others

	2023	2022	2021
Tax Expense Rate	-20.08%	-1.19%	-0.21%

# ACADIA PHARMACEUTICALS INC.

ISIN: US0042251084 WKN: 004225108 Asset Class: Stock

### Income statement

	2023	2022	2021
Turnover	-	-	-
Net income	-	-	-
EBIT	-64,126,011	-206,696,722	-157,905,723
Operating income before taxes	-	-	-
Cash Flow	-	-	-
Net interest income	-	-	-
Research and development expenses	-	-	-
Income taxes	-	-	-
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	1,141,041	947,054	884,742

#### **Board of Directors**

## Members of Management Board

Stephen Biggar	Chairman of Board of Directors
Adora Ndu	Member of Board of Directors
Edmund Harrigan	Member of Board of Directors
Elizabeth Garofalo	Member of Board of Directors
Daniel Soland	Member of Board of Directors
James Daly	Member of Board of Directors
Julian Baker	Member of Board of Directors
Laura Brege	Member of Board of Directors